Where does Cempra Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cempra Pharmaceuticals, Inc. ranks #19,586 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cempra Pharmaceuticals, Inc. hold?

Cempra Pharmaceuticals, Inc. holds 14 US utility patents granted between 2015 and 2019, spanning 6 technology areas.

What is Cempra Pharmaceuticals, Inc.'s Innovation Score?

Cempra Pharmaceuticals, Inc. has an Innovation Score of 32.9 out of 100 (43rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cempra Pharmaceuticals, Inc. focus on?

Cempra Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Cempra Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Cempra Pharmaceuticals, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cempra Pharmaceuticals, Inc.'s patents?

Cempra Pharmaceuticals, Inc.'s patents average 24.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cempra Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cempra Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 14 granted patents across 6 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cempra ranks #19,586 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 6 technology areas.

#19,586
of 49,997 US assignees by volume: 43rd percentile
by Innovation Score (32.9/100): 24.8
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19586 · US Corporation #19,586 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,586/49,997
PHOTO-FINISH Celerint
CPC-NARROW A61P · 6 areas
INNOV-THIN 32.9/100
CLAIMS-DENSE 24.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Celerint, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cempra’s 32.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (28%) Velocity 0.0 pts (0%) Breadth 8.7 pts (26%) Claim depth 14.9 pts (45%)

Qualcomm Incorporated · highest

85
Cempra Pharmaceuticals · this assignee

33
3D Lighting… · lowest

7

What this shows Cempra's Innovation Score is 32.9/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cempra?

Each dot is one of Cempra’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cempra’s own 24.8 claims/patent is ABOVE the 9.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cempra vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cempra's grants concentrate

Cempra Pharmaceuticals, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2019. By volume, Cempra sits between Celerint, LLC and China Pneumatic Corporation.

Celerint

14
Cellcentric & KG

14
Cellivery Therape…

14
Cellresearch PTE

14
Certis Cisco Secu…

14
Certoplast Techni…

14
Checkmate Lifting…

14
China Pneumatic

14
Cempra Pharmaceut… ◀

14

What this shows Cempra holds 14 patents at rank #19,571, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cempra

By rank, the assignees closest to #19,571 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cempra's primary technology class.

Cempra's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cempra Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	21.4%
2016	3	21.4%
2017	3	21.4%
2018	4	28.6%
2019	1	7.1%

Which technologies does Cempra Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07D - Heterocyclic Compounds 6

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cempra Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Cempra Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #19,586 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cempra Pharmaceuticals, Inc. against Celerint, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.